Most New Drugs Fail to Recoup Development Costs
IQVIA report finds the share of profitable U.S. medicines has fallen to a record low.
Updated on Nov. 16, 2026 in Healthcare

Live Poll
Do you think new prescription drug development in the U.S. is getting better or worse?
A new IQVIA analysis of 825 novel medicines launched in the U.S. from 1991 to 2020 finds that about 90% of drugs launched from 2016 to 2020 are projected to generate insufficient lifetime revenues to cover their costs. IQVIA says the share of medicines generating a positive return on investment has fallen to an all-time low.
Why it matters
The findings suggest that the economics of drug development in the United States have shifted sharply, with rising research costs and shorter product life cycles raising the sales needed for a medicine to pay off. Because the analysis projects that none of the drugs launched in 2020 will generate a positive return, the trend bears on how future treatments are funded and brought to market.
Capitalized R&D cost per new medicine rose from about $366 million in 1991 to $3.2 billion in 2020, and about 44% of analyzed products generated less than $1 billion in lifetime revenue. Those products accounted for only 4% of aggregate industry revenues.
The players
IQVIA
IQVIA is a global provider of clinical research and healthcare data and analytics that publishes widely cited reports on the pharmaceutical industry.
The details
IQVIA assessed lifetime revenues, operating costs, taxes and capitalized R&D spending for each drug to evaluate returns over time. The firm attributed the rising sales threshold to shortening life cycles, stable operating costs, rising R&D spending and falling success rates.
Timeline
Launches from 1991 to 1995 averaged a lifetime return of $555 million.
Launches from 2001 to 2005 saw average lifetime returns rise to $644 million.
Launches from 2006 to 2010 saw average lifetime returns turn negative.
Launches from 2016 to 2020 are projected to be largely unprofitable.
Base-case R&D cost per medicine reached $3.2 billion by 2020.
Market Landscape
The decline tracks a multi-decade series of IQVIA cohort analyses showing that medicines launched in the early 1990s were far more likely to pay back their costs than those launched in the 2010s. The pattern points to a widening gap between what drug developers spend and what the market returns on their products.
Rising development costs and falling returns may influence which treatments companies pursue and how quickly new medicines reach patients. Readers with exposure to pharmaceutical stocks or retirement funds holding healthcare sector assets may see the trend reflected in long-term sector performance.
The takeaway
The economics of new drug development have tightened considerably over three decades, making the commercial success of any single launch harder to predict. Watching how companies respond to these pressures can help readers understand future drug pricing and innovation trends.
Further reading
For broader context on how drug pricing and development costs shape the sector, explore Healthcare coverage.
Source note: This article includes information reported by Pharma.
Live Poll
Do you think new prescription drug development in the U.S. is getting better or worse?






